The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The combination of hypomethylating agents and histone deacetylase inhibitors produce marked synergy in preclinical models of T-cell lymphoma
Authors
Keywords
-
Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 171, Issue 2, Pages 215-226
Publisher
Wiley
Online
2015-07-21
DOI
10.1111/bjh.13566
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma
- (2013) J. E. Amengual et al. BLOOD
- Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors
- (2013) Vivien Mak et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study
- (2013) Pier Paolo Piccaluga et al. JOURNAL OF CLINICAL ONCOLOGY
- IMA: an R package for high-throughput analysis of Illumina's 450K Infinium methylation data
- (2012) D. Wang et al. BIOINFORMATICS
- Brentuximab Vedotin
- (2012) C. Deng et al. CLINICAL CANCER RESEARCH
- Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy
- (2012) Bertrand Coiffier et al. JOURNAL OF CLINICAL ONCOLOGY
- The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
- (2012) Peter D Senter et al. NATURE BIOTECHNOLOGY
- Gene expression analysis uncovers similarity and differences among Burkitt lymphoma subtypes
- (2011) P. P. Piccaluga et al. BLOOD
- HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
- (2011) M. Kalac et al. BLOOD
- Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study
- (2011) Owen A. O'Connor et al. JOURNAL OF CLINICAL ONCOLOGY
- Pralatrexate Is Synergistic with the Proteasome Inhibitor Bortezomib in In vitro and In vivo Models of T-Cell Lymphoid Malignancies
- (2010) E. Marchi et al. CLINICAL CANCER RESEARCH
- Romidepsin and Belinostat Synergize the Antineoplastic Effect of Bortezomib in Mantle Cell Lymphoma
- (2010) L. Paoluzzi et al. CLINICAL CANCER RESEARCH
- Targeted treatment and new agents in peripheral T-cell lymphoma
- (2010) Jasmine M. Zain et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Emerging role of epigenetic therapies in cutaneous T-cell lymphomas
- (2010) Jasmine Zain et al. Expert Review of Hematology
- Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma
- (2009) Susan E. Bates et al. BRITISH JOURNAL OF HAEMATOLOGY
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
- (2009) Da Wei Huang et al. Nature Protocols
- Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma
- (2008) L. Paoluzzi et al. BLOOD
- Gene expression analysis provides a potential rationale for revising the histological grading of follicular lymphomas
- (2008) P. P. Piccaluga et al. HAEMATOLOGICA
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now